^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Avzivi (bevacizumab-tnjn) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/06/2023
Excerpt:
Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of:…Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
Secondary therapy:
cisplatin + paclitaxel; paclitaxel + topotecan
